Additionally, the dependence of FRA-1 activity on ERK activation suggests that tumors (such as pancreatic cancer) bearing activating mutations with the Ras-Raf-MEK-ERK cascade are likely to exhibit FRA-1 based effects. The gene discussed is FOSL1; the disease is pancreatic neoplasm.